Selank

Selank is a short peptide, specifically a synthetic analogue of a human tetrapeptide Tuftsin. It is an anxiolytic peptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is believed to modulate the expression of brain-derived neurotrophic factor (BDNF) in rats. It has been studied for its potential therapeutic effects on anxiety, depression, and cognitive function. Selank is administered intranasally, allowing it to bypass the blood-brain barrier more effectively than other administration routes. While research suggests potential benefits, it is crucial to note that Selank is not approved for medical use in many countries, and its safety and efficacy in humans require further rigorous clinical trials. Its mechanism of action is thought to involve influencing the balance of neurotransmitters and neuropeptides in the brain, particularly those associated with anxiety and mood regulation.